Physician profile
Alan D Grover
NPI 1760672331
$1,215.64
in general payments reported to CMS, 2019-2025
19 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.54 · 2020: $69.15 · 2021: $177 · 2022: $240 · 2023: $222 · 2024: $108 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $287.93 | 2022-2025 | Miebo, Vyzulta, Infuse |
| Tarsus Pharmaceuticals, INC. | $132.07 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $121.23 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $111.09 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $92.34 | 2021-2025 | |
| Abbvie INC. | $66.01 | 2022-2025 | |
| Allergan, INC. | $63.90 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $58.94 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $57.85 | 2022-2025 | Cequa |
| Horizon Therapeutics Plc | $39.45 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $34.41 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Novartis Pharmaceuticals Corporation | $30.67 | 2021-2023 | |
| Oyster Point Pharma, INC. | $29.43 | 2022-2023 | Tyrvaya |
| Glaukos Corporation | $17.82 | 2025 | Idosetr, Istent Infinite |
| Kowa Pharmaceuticals America, INC. | $15.10 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $15.04 | 2021 | |
| Alcon Vision LLC | $14.84 | 2019 | |
| Sight Sciences, INC. | $14.11 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.